Penn Spinoff CAR-M Called “CT-0508” Attacks Solid Tumors in Preclinical—Now in Phase 1 Study

Penn Spinoff CAR-M Called “CT-0507” Attacks Solid Tumors in Preclinical—Now in Phase 1 Study

The U.S. Food and Drug Administration (FDA) granted fast track designation to CARISMA Therapeutics, a biopharmaceutical company focused on discovering and developing innovative immunotherapies. Specifically, the designation is for their investigational product called CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M) for the treatment of solid tumors. This represents a key milestone in the company's mission to develop gene-based cell therapies. The experimental product was developed by Saar Gill, MD, Ph.D., Scientific Co-founder, and Senior Vice President of Discovery at CARISMA Therapeutics, and an Associate Professor of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania; and Michael Klichinsky, PharmD, Ph.D., Scientific Co-founder, and Senior Vice President of Discovery at CARISMA Therapeutics. The investigational therapy has under investigation in a first-in-human Phase 1 multi-center clinical trial focusing on patients with recurrent or metastatic HER2 overexpressing solid tumors whose cancers do not have any approved HER2-targeted therapies or who do not respond to treatment.

...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee